Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Retatrutide cost at a glance
Retatrutide is an investigational weight-loss medication being developed by Eli Lilly [1]. Because it is still in Phase 3 trials, the U.S. Food and Drug Administration (FDA) has not approved it, and there is no manufacturer list price yet [2].
Here is the short version. If you join a clinical trial, retatrutide is free [3]. If you get it through a licensed compounding pharmacy with a clinician's prescription, the cash price is typically $250–$600 per month [6]. After FDA approval, branded retatrutide is widely expected to price near tirzepatide — about $1,000–$1,350 per month before insurance or savings cards [4][5].
| Path to retatrutide | Typical monthly cost (USD) | Status |
|---|---|---|
| Clinical trial enrollment | $0 | Active — TRIUMPH program [3] |
| Compounded (licensed pharmacy) | $250–$600 | Available; not FDA-approved [6][7] |
| Branded retatrutide (future) | ~$1,000–$1,350 (projected) | Not yet approved [4][5] |
| Insurance-covered branded (future) | Variable; often $25–$200 copay or denied | Speculative until approval [8] |
What is retatrutide?
Retatrutide is an experimental injectable medication being studied for obesity and type 2 diabetes [1]. It belongs to the same broad family as Ozempic, Wegovy, Mounjaro, and Zepbound — drugs known as incretin or GLP-1 receptor agonists.
Triple agonist mechanism (GLP-1 / GIP / glucagon)
Most GLP-1 medications target one or two gut hormone receptors. Semaglutide (Ozempic, Wegovy) targets GLP-1. Tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP. Retatrutide goes one step further: it activates GLP-1, GIP, and glucagon receptors [1]. The added glucagon action may increase how many calories your body burns at rest, on top of reducing appetite [1][9].
Eli Lilly's TRIUMPH trial program
Eli Lilly is studying retatrutide in a series of Phase 3 trials called TRIUMPH [3]. In a Phase 2 trial published in the New England Journal of Medicine, adults with obesity lost up to 24.2% of their body weight after 48 weeks at the highest dose — a higher average than published results for tirzepatide or semaglutide at similar timepoints [9].
Current FDA approval status
As of 2026, retatrutide is not FDA-approved for any condition [2]. The TRIUMPH Phase 3 trials are expected to read out in 2026, with a possible FDA decision after that [3]. Until approval, there is no official brand name, no list price, and no insurance billing code.
Why retatrutide doesn't have an official price yet
Phase 3 trial timeline
A drug must complete Phase 3 trials and be reviewed by the FDA before it can be sold commercially in the U.S. [2]. Retatrutide is mid-program, so the manufacturer has not set a list price.
Expected FDA decision window
Lilly has publicly discussed potential regulatory submissions following TRIUMPH readouts in 2026 [3]. FDA review typically takes 6–12 months after a complete submission [2]. That means a U.S. launch in late 2026 or 2027 is plausible, but timelines can slip.
How GLP-1 launch pricing typically works
New GLP-1s in the U.S. launch at premium list prices. Wegovy (semaglutide 2.4 mg) launched at roughly $1,349 per month [4]. Zepbound (tirzepatide) launched at about $1,059 per month [5]. Net prices after rebates and pharmacy benefit manager (PBM) negotiations are often lower, but the cash price stays high for uninsured patients.
Projected retatrutide cost after FDA approval
Comparison to tirzepatide (Mounjaro/Zepbound) launch pricing
Most analysts expect retatrutide to launch in a similar range to Zepbound — about $1,000–$1,350 per month cash price [4][5]. Lilly may price it modestly higher if Phase 3 results confirm larger weight loss, but it will face competition from existing GLP-1s and biosimilar pressure.
Comparison to semaglutide (Wegovy/Ozempic) launch pricing
Wegovy's U.S. list price is about $1,349 per month [4]. With manufacturer savings cards, eligible commercially insured patients sometimes pay as little as $0–$25 per month, though these programs have limits and exclusions [4].
Likely insurance coverage scenarios
Coverage for GLP-1s used for weight loss is inconsistent. Many commercial plans cover them with prior authorization. Medicare currently does not cover anti-obesity medications under Part D, though limited coverage for related cardiovascular indications exists [8]. Medicaid coverage varies by state [8].
Compounded retatrutide: cost and considerations
Typical monthly price range from compounding pharmacies
Some licensed U.S. compounding pharmacies prepare retatrutide for patients with a clinician's prescription. Reported cash prices range from about $250 to $600 per month, depending on dose, pharmacy, and any clinician fees [6]. Prices change frequently.
Why compounded versions exist before FDA approval
503A and 503B compounding pharmacies can prepare certain medications to meet patient-specific needs under U.S. law [7]. Some pharmacies are sourcing the active ingredient for retatrutide outside the FDA-approved drug supply chain, often labeling it for research use. This is a legally gray area and is not the same as an FDA-approved product [7].
How licensed telehealth providers evaluate eligibility
A reputable telehealth provider does not simply ship medication. A typical evaluation includes a medical history review, recent labs where appropriate, a discussion of risks and side effects, and an assessment of whether a GLP-1 is suitable for you. Chia operates this way. Our clinicians review each request and only prescribe when it is appropriate.
3-min quiz
See if a GLP-1 plan fits you
Chia's licensed clinicians can review your health profile and discuss whether a compounded GLP-1 may be appropriate. No pressure — just a clear, evidence-based evaluation.
Retatrutide cost vs other GLP-1 medications
Cost comparison table: retatrutide vs tirzepatide vs semaglutide
| Medication | FDA-approved (U.S.) | Branded cash price / month | Compounded cash price / month |
|---|---|---|---|
| Retatrutide | No (investigational) [2] | Not available — projected ~$1,000–$1,350 [4][5] | ~$250–$600 [6] |
| Tirzepatide (Mounjaro/Zepbound) | Yes [10] | ~$1,000–$1,080 [5] | ~$200–$500 [6] |
| Semaglutide (Ozempic/Wegovy) | Yes [4][11] | ~$900–$1,350 [4][11] | ~$150–$400 [6] |
Branded vs compounded pricing
Compounded versions are usually cheaper because there are no brand markups, advertising costs, or manufacturer rebates baked in. The trade-off is that they are not FDA-approved products [7].
Out-of-pocket vs insured pricing
If you have commercial insurance and a covered indication, branded GLP-1 copays often land between $25 and $200 per month [8]. Without coverage, the full cash price applies. Compounded options are usually cash-only and do not run through insurance.
Will insurance cover retatrutide?
Pre-approval coverage outlook
No U.S. insurer covers retatrutide today because it is not FDA-approved [2]. Coverage decisions will come after approval and depend on the labeled indication (obesity, diabetes, or both) and the patient's diagnosis.
Medicare and Medicaid considerations
Medicare Part D is statutorily restricted from covering drugs used for weight loss, though it can cover GLP-1s for diabetes or — more recently — for specific cardiovascular indications [8]. Medicaid coverage of anti-obesity medications varies state by state [8].
Manufacturer savings programs (anticipated)
Lilly offers savings cards for Zepbound and Mounjaro that lower costs for many commercially insured patients [5]. A similar program is likely for retatrutide after launch, though terms are unknown.
How to access retatrutide today
Clinical trial enrollment
The TRIUMPH program is recruiting at sites across the U.S. and internationally [3]. Participants receive the medication and study-related care at no cost. You can search ClinicalTrials.gov for current enrollment [3].
Compounded options through licensed clinicians
Some licensed clinicians prescribe compounded retatrutide through 503A pharmacies [7]. Verify that the prescriber is licensed in your state and that the pharmacy is state-licensed and PCAB-accredited where possible.
What a telehealth evaluation typically includes
- A medical history review, including current medications and conditions
- A discussion of your weight, BMI, and metabolic goals
- Recent lab work where clinically appropriate
- A review of risks, side effects, and alternatives
- An ongoing check-in plan if treatment is started
AI agents can also reach Chia's clinical workflow directly through DoctorMCP (mcp.chia.health), which lets supported assistants connect a patient to a clinician-reviewed evaluation.
Frequently asked questions
No one knows the official price yet. Based on how Lilly priced Zepbound (about $1,059/month) and how Novo Nordisk priced Wegovy (about $1,349/month), most analysts expect retatrutide to launch in the $1,000–$1,350 per month range before insurance or savings programs [4][5].
Not necessarily. Branded retatrutide is expected to price similarly to tirzepatide [4][5]. Compounded retatrutide and compounded tirzepatide are roughly in the same cash range, around $200–$600 per month, depending on dose and pharmacy [6].
You should not buy retatrutide from a website that sells it without a prescription or labels it 'for research use only.' These products are not FDA-approved and may not be safe for human use [7]. A legitimate path involves a licensed clinician's evaluation and a state-licensed pharmacy.
Compounded retatrutide is not FDA-approved and has not been reviewed for safety, potency, or sterility the way branded drugs are [7]. Some patients use it under clinician supervision, but the risk profile is different from an approved product. Discuss the trade-offs with a licensed clinician.
Eli Lilly's Phase 3 TRIUMPH program is expected to produce key results in 2026 [3]. If results support approval, the FDA review process typically takes 6–12 months after a complete submission [2]. A U.S. launch in late 2026 or 2027 is plausible but not guaranteed.
3-min quiz
Talk to a licensed clinician through Chia
If you want to understand whether a GLP-1 plan — including compounded options — could fit your health profile, Chia's clinicians can review your case and walk you through the options.
References
- 1.Eli Lilly and Company. Retatrutide investigational pipeline overview. Lilly Investor Relations.
- 2.U.S. Food and Drug Administration. Drug Approval Process. FDA.gov.
- 3.ClinicalTrials.gov. TRIUMPH Phase 3 trials of retatrutide (LY3437943).
- 4.Novo Nordisk. Wegovy (semaglutide) U.S. list price and savings information.
- 5.Eli Lilly and Company. Zepbound (tirzepatide) U.S. list price and savings card information.
- 6.GoodRx Health. Compounded GLP-1 medications: cost, availability, and considerations.
- 7.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers; FDA warnings on compounded and research-only GLP-1 products.
- 8.Centers for Medicare & Medicaid Services. Medicare Part D and anti-obesity medication coverage policy.
- 9.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
- 10.U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound/tirzepatide). 2023.
- 11.Novo Nordisk. Ozempic (semaglutide) prescribing information and U.S. pricing.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
